🔎 Trials Near Me

Home › Lung Cancer › NCT05281237

Avecure Flexible Microwave Ablation Probe For Lung Nodules

Recruiting

Feasibility and Efficacy of the AveCure Flexible Microwave Ablation Probe for Peripheral Lung Nodule

Who can join

Ages 22 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Subject with Stage I - II primary lung cancer (Solitary nodules up to 3 cm) as defined by previous pathology or ROSE.
* Pathological proof of target nodule/tumor type and malignancy with specimen considered adequate per institutional laboratory standards
* Target nodule/tumor which can be accessed via navigational bronchoscopy and confirmed location with cone beam CT scan intra-operatively
* Resection/surgical candidate (lobectomy or greater)
* Participants must be at least 22 years old and able to provide consent

Exclusion Criteria:

* Subjects in whom flexible bronchoscopy is contraindicated
* Target nodule \< 1.0 cm
* Prior radiation or neo adjuvant chemotherapy of the target nodule/tumor
* Any comorbidity that the investigator feels would interfere with the safety of the subject or the evaluation of study objectives
* Pacemaker, implantable cardioverter, or another electronic implantable device
* Patient cannot tolerate bronchoscopy
* Patients with coagulopathy
* Patients in other therapeutic lung cancer studies
* Subject is pregnant or breastfeeding
* COVID-19 positive patient at the time of procedure.

About the study

This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size.

This research study involves microwave ablation (MWA)

What is being tested

Sponsor: Beth Israel Deaconess Medical Center · Participants: 10 · Started: Jun 1, 2022

Contact the study team

Official record on ClinicalTrials.gov — NCT05281237

Locations in the U.S.

MassachusettsBeth Israel Deaconess Medical Center, Boston

Conditions

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.